Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) have been given a consensus rating of “Buy” by the seven analysts that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $42.67.

Several equities research analysts have commented on the stock. Wedbush restated an “outperform” rating and set a $50.00 target price on shares of Scholar Rock in a research report on Wednesday. Lifesci Capital upgraded shares of Scholar Rock to a “strong-buy” rating in a research report on Tuesday, June 3rd.

Insider Transactions at Scholar Rock

In related news, insider Akshay Vaishnaw sold 6,750 shares of the business’s stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $29.72, for a total value of $200,610.00. Following the completion of the transaction, the insider now owns 616,205 shares of the company’s stock, valued at approximately $18,313,612.60. The trade was a 1.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey S. Flier sold 6,075 shares of the business’s stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $29.73, for a total transaction of $180,609.75. Following the completion of the transaction, the director now directly owns 24,070 shares of the company’s stock, valued at $715,601.10. The trade was a 20.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,500 shares of company stock valued at $1,181,671 in the last 90 days. 13.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. CWM LLC raised its stake in Scholar Rock by 152.8% in the 1st quarter. CWM LLC now owns 996 shares of the company’s stock valued at $32,000 after purchasing an additional 602 shares during the last quarter. Global Retirement Partners LLC raised its stake in Scholar Rock by 584.7% in the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after purchasing an additional 766 shares during the last quarter. Federated Hermes Inc. acquired a new position in Scholar Rock in the 1st quarter valued at about $71,000. GF Fund Management CO. LTD. raised its stake in Scholar Rock by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,396 shares of the company’s stock valued at $77,000 after purchasing an additional 430 shares during the last quarter. Finally, Strs Ohio acquired a new position in Scholar Rock in the 1st quarter valued at about $77,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Price Performance

Shares of NASDAQ SRRK opened at $34.04 on Friday. The firm has a market capitalization of $3.23 billion, a P/E ratio of -13.45 and a beta of 0.28. Scholar Rock has a one year low of $6.76 and a one year high of $46.98. The company’s fifty day moving average is $31.65 and its two-hundred day moving average is $36.04. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.25 and a current ratio of 10.25.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period in the prior year, the firm posted ($0.59) EPS. Analysts forecast that Scholar Rock will post -2.42 EPS for the current fiscal year.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.